APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Peptide CDMO

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Peptide CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174023610329 December 2025198 pages

Choose your research edition.

Industry ResearchPeptide CDMO Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide CDMO Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Peptide CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide CDMO Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide CDMO Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Peptide CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Peptide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Peptide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Peptide CDMO include Xinbang Pharma, ScinoPharm, SN Biopharm, Genscript, AmbioPharm, USV Peptides, Thermofischer, PolyPeptide and Piramal Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Peptide CDMO market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide CDMO and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide CDMO revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Peptide CDMO market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide CDMO Segment by Company

Xinbang Pharma

ScinoPharm

SN Biopharm

Genscript

AmbioPharm

USV Peptides

Thermofischer

PolyPeptide

Piramal Pharma

JPT

CPC Scientific

CordenPharma

CBL

Bio Basic

Bachem

Peptide CDMO Segment by Type

APIs and Intermediates

FDF

Peptide CDMO Segment by Application

Commercial

Academic Research

Other

Peptide CDMO Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Peptide CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide CDMO industry.

Chapter 3: Detailed analysis of Peptide CDMO companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide CDMOrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peptide CDMO Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of APIs and Intermediates Table 3. Key Players of FDF Table 4. Global Peptide CDMO Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Commercial Table 6. Key Players of Academic Research Table 7. Key Players of Other Table 8. Global Peptide CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Peptide CDMO Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Peptide CDMO Market Share by Region (2021-2026) Table 11. Global Peptide CDMO Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Peptide CDMO Market Share by Region (2027-2032) Table 13. Peptide CDMO Industry Trends Table 14. Peptide CDMO Industry Drivers Table 15. Peptide CDMO Industry Opportunities and Challenges Table 16. Peptide CDMO Industry Restraints Table 17. Global Peptide CDMO Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Peptide CDMO Revenue Market Share by Company (2021-2026) Table 19. Global Peptide CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Peptide CDMO Key Company Head Office and Area Served Table 21. Global Peptide CDMO Company, Product Type & Application Table 22. Global Peptide CDMO Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Peptide CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Peptide CDMO Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Peptide CDMO Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Peptide CDMO Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Peptide CDMO Revenue Market Share by Type (2021-2026) Table 29. Global Peptide CDMO Revenue Market Share by Type (2027-2032) Table 30. Global Peptide CDMO Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Peptide CDMO Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Peptide CDMO Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Peptide CDMO Revenue Market Share by Application (2021-2026) Table 34. Global Peptide CDMO Revenue Market Share by Application (2027-2032) Table 35. Xinbang Pharma Company Information Table 36. Xinbang Pharma Business Overview Table 37. Xinbang Pharma Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Xinbang Pharma Peptide CDMO Product Portfolio Table 39. Xinbang Pharma Recent Development Table 40. ScinoPharm Company Information Table 41. ScinoPharm Business Overview Table 42. ScinoPharm Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. ScinoPharm Peptide CDMO Product Portfolio Table 44. ScinoPharm Recent Development Table 45. SN Biopharm Company Information Table 46. SN Biopharm Business Overview Table 47. SN Biopharm Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. SN Biopharm Peptide CDMO Product Portfolio Table 49. SN Biopharm Recent Development Table 50. Genscript Company Information Table 51. Genscript Business Overview Table 52. Genscript Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Genscript Peptide CDMO Product Portfolio Table 54. Genscript Recent Development Table 55. AmbioPharm Company Information Table 56. AmbioPharm Business Overview Table 57. AmbioPharm Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. AmbioPharm Peptide CDMO Product Portfolio Table 59. AmbioPharm Recent Development Table 60. USV Peptides Company Information Table 61. USV Peptides Business Overview Table 62. USV Peptides Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. USV Peptides Peptide CDMO Product Portfolio Table 64. USV Peptides Recent Development Table 65. Thermofischer Company Information Table 66. Thermofischer Business Overview Table 67. Thermofischer Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Thermofischer Peptide CDMO Product Portfolio Table 69. Thermofischer Recent Development Table 70. PolyPeptide Company Information Table 71. PolyPeptide Business Overview Table 72. PolyPeptide Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. PolyPeptide Peptide CDMO Product Portfolio Table 74. PolyPeptide Recent Development Table 75. Piramal Pharma Company Information Table 76. Piramal Pharma Business Overview Table 77. Piramal Pharma Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Piramal Pharma Peptide CDMO Product Portfolio Table 79. Piramal Pharma Recent Development Table 80. JPT Company Information Table 81. JPT Business Overview Table 82. JPT Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. JPT Peptide CDMO Product Portfolio Table 84. JPT Recent Development Table 85. CPC Scientific Company Information Table 86. CPC Scientific Business Overview Table 87. CPC Scientific Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. CPC Scientific Peptide CDMO Product Portfolio Table 89. CPC Scientific Recent Development Table 90. CordenPharma Company Information Table 91. CordenPharma Business Overview Table 92. CordenPharma Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 93. CordenPharma Peptide CDMO Product Portfolio Table 94. CordenPharma Recent Development Table 95. CBL Company Information Table 96. CBL Business Overview Table 97. CBL Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 98. CBL Peptide CDMO Product Portfolio Table 99. CBL Recent Development Table 100. Bio Basic Company Information Table 101. Bio Basic Business Overview Table 102. Bio Basic Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 103. Bio Basic Peptide CDMO Product Portfolio Table 104. Bio Basic Recent Development Table 105. Bachem Company Information Table 106. Bachem Business Overview Table 107. Bachem Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 108. Bachem Peptide CDMO Product Portfolio Table 109. Bachem Recent Development Table 110. North America Peptide CDMO Market Size by Type (2021-2026) & (US$ Million) Table 111. North America Peptide CDMO Market Size by Type (2027-2032) & (US$ Million) Table 112. North America Peptide CDMO Market Size by Application (2021-2026) & (US$ Million) Table 113. North America Peptide CDMO Market Size by Application (2027-2032) & (US$ Million) Table 114. North America Peptide CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America Peptide CDMO Market Size by Country (2021-2026) Table 116. North America Peptide CDMO Market Size by Country (2027-2032) Table 117. Europe Peptide CDMO Market Size by Type (2021-2026) & (US$ Million) Table 118. Europe Peptide CDMO Market Size by Type (2027-2032) & (US$ Million) Table 119. Europe Peptide CDMO Market Size by Application (2021-2026) & (US$ Million) Table 120. Europe Peptide CDMO Market Size by Application (2027-2032) & (US$ Million) Table 121. Europe Peptide CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Europe Peptide CDMO Market Size by Country (2021-2026) Table 123. Europe Peptide CDMO Market Size by Country (2027-2032) Table 124. China Peptide CDMO Market Size by Type (2021-2026) & (US$ Million) Table 125. China Peptide CDMO Market Size by Type (2027-2032) & (US$ Million) Table 126. China Peptide CDMO Market Size by Application (2021-2026) & (US$ Million) Table 127. China Peptide CDMO Market Size by Application (2027-2032) & (US$ Million) Table 128. Asia Peptide CDMO Market Size by Type (2021-2026) & (US$ Million) Table 129. Asia Peptide CDMO Market Size by Type (2027-2032) & (US$ Million) Table 130. Asia Peptide CDMO Market Size by Application (2021-2026) & (US$ Million) Table 131. Asia Peptide CDMO Market Size by Application (2027-2032) & (US$ Million) Table 132. Asia Peptide CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Asia Peptide CDMO Market Size by Country (2021-2026) Table 134. Asia Peptide CDMO Market Size by Country (2027-2032) Table 135. South America, Middle East & Africa Peptide CDMO Market Size by Type (2021-2026) & (US$ Million) Table 136. South America, Middle East & Africa Peptide CDMO Market Size by Type (2027-2032) & (US$ Million) Table 137. South America, Middle East & Africa Peptide CDMO Market Size by Application (2021-2026) & (US$ Million) Table 138. South America, Middle East & Africa Peptide CDMO Market Size by Application (2027-2032) & (US$ Million) Table 139. South America, Middle East & Africa Peptide CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. South America, Middle East & Africa Peptide CDMO Market Size by Country (2021-2026) Table 141. South America, Middle East & Africa Peptide CDMO Market Size by Country (2027-2032) Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Peptide CDMO Product Image Figure 2. Global Peptide CDMO Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Peptide CDMO Market Share by Type: 2025 VS 2032 Figure 4. APIs and Intermediates Image Figure 5. FDF Image Figure 6. Global Peptide CDMO Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Peptide CDMO Market Share by Application: 2025 VS 2032 Figure 8. Commercial Image Figure 9. Academic Research Image Figure 10. Other Image Figure 11. Global Peptide CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 13. Global Peptide CDMO Market Share by Region: 2025 VS 2032 Figure 14. Years Considered Figure 15. Global Peptide CDMO Market Share by Players in 2025 Figure 16. Global Top 5 and 10 Peptide CDMO Players Market Share by Revenue in 2025 Figure 17. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Peptide CDMO Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Peptide CDMO Revenue Market Share by Type (2021-2032) Figure 20. Global Peptide CDMO Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Peptide CDMO Revenue Market Share by Application (2021-2032) Figure 22. North America Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 23. North America Peptide CDMO Market Share by Type (2021-2032) Figure 24. North America Peptide CDMO Market Share by Application (2021-2032) Figure 25. North America Peptide CDMO Market Share by Country (2021-2032) Figure 26. United States Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 27. Canada Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 28. Mexico Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 29. Europe Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 30. Europe Peptide CDMO Market Share by Type (2021-2032) Figure 31. Europe Peptide CDMO Market Share by Application (2021-2032) Figure 32. Europe Peptide CDMO Market Share by Country (2021-2032) Figure 33. Germany Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 34. France Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 35. U.K. Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 36. Italy Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 37. Russia Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 38. Nordic Countries Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 39. China Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 40. China Peptide CDMO Market Share by Type (2021-2032) Figure 41. China Peptide CDMO Market Share by Application (2021-2032) Figure 42. Asia Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 43. Asia Peptide CDMO Market Share by Type (2021-2032) Figure 44. Asia Peptide CDMO Market Share by Application (2021-2032) Figure 45. Asia Peptide CDMO Market Share by Country (2021-2032) Figure 46. Japan Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 47. South Korea Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 48. Taiwan Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 49. Southeast Asia Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 50. India Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 51. Australia Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Peptide CDMO Market Share by Type (2021-2032) Figure 54. South America, Middle East & Africa Peptide CDMO Market Share by Application (2021-2032) Figure 55. South America, Middle East & Africa Peptide CDMO Market Share by Country (2021-2032) Figure 56. Brazil Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 57. South Africa Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 59. Turkey Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 60. Argentina Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 61. UAE Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 62. Egypt Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 63. Chile Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Types
  • APIs and Intermediates
  • FDF
Applications
  • Commercial
  • Academic Research
  • Other
Companies covered
  • Xinbang Pharma
  • ScinoPharm
  • SN Biopharm
  • Genscript
  • AmbioPharm
  • USV Peptides
  • Thermofischer
  • PolyPeptide
  • Piramal Pharma
  • JPT
  • CPC Scientific
  • CordenPharma
  • CBL
  • Bio Basic
  • Bachem

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Peptide CDMO Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 APIs and Intermediates
  5. 1.2.3 FDF
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Peptide CDMO Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Commercial
  9. 1.3.3 Academic Research
  10. 1.3.4 Other
  11. 1.4 Global Market Growth Prospects
  12. 1.5 Global Peptide CDMO Growth Trends by Region
  13. 1.5.1 Global Peptide CDMO Market Size by Region: 2021 VS 2025 VS 2032
  14. 1.5.2 Peptide CDMO Market Size by Region (2021-2026)
  15. 1.5.3 Peptide CDMO Market Size by Region (2027-2032)
  16. 1.6 Assumptions and Limitations
  17. 1.7 Study Goals and Objectives
  18. 1.8 Years Considered
2 Global Peptide CDMO Market Dynamics
  1. 2.1 Peptide CDMO Industry Trends
  2. 2.2 Peptide CDMO Industry Drivers
  3. 2.3 Peptide CDMO Industry Opportunities and Challenges
  4. 2.4 Peptide CDMO Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Peptide CDMO Revenue by Company (2021-2026)
  2. 3.2 Global Peptide CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Peptide CDMO Key Company Head office and Area Served
  4. 3.4 Global Peptide CDMO Company, Product Type & Application
  5. 3.5 Global Peptide CDMO Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Peptide CDMO Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Peptide CDMO Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Peptide CDMO Tier 1, Tier 2, and Tier 3
4 Peptide CDMO Market by Type
  1. 4.1 Global Peptide CDMO Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Peptide CDMO Market Size by Type (2021-2032)
  3. 4.3 Global Peptide CDMO Market Size Share by Type (2021-2032)
5 Peptide CDMO Market by Application
  1. 5.1 Global Peptide CDMO Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Peptide CDMO Market Size by Application (2021-2032)
  3. 5.3 Global Peptide CDMO Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Xinbang Pharma
  2. 6.1.1 Xinbang Pharma Company Information
  3. 6.1.2 Xinbang Pharma Business Overview
  4. 6.1.3 Xinbang Pharma Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Xinbang Pharma Peptide CDMO Product Portfolio
  6. 6.1.5 Xinbang Pharma Recent Developments
  7. 6.2 ScinoPharm
  8. 6.2.1 ScinoPharm Company Information
  9. 6.2.2 ScinoPharm Business Overview
  10. 6.2.3 ScinoPharm Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 ScinoPharm Peptide CDMO Product Portfolio
  12. 6.2.5 ScinoPharm Recent Developments
  13. 6.3 SN Biopharm
  14. 6.3.1 SN Biopharm Company Information
  15. 6.3.2 SN Biopharm Business Overview
  16. 6.3.3 SN Biopharm Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 SN Biopharm Peptide CDMO Product Portfolio
  18. 6.3.5 SN Biopharm Recent Developments
  19. 6.4 Genscript
  20. 6.4.1 Genscript Company Information
  21. 6.4.2 Genscript Business Overview
  22. 6.4.3 Genscript Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Genscript Peptide CDMO Product Portfolio
  24. 6.4.5 Genscript Recent Developments
  25. 6.5 AmbioPharm
  26. 6.5.1 AmbioPharm Company Information
  27. 6.5.2 AmbioPharm Business Overview
  28. 6.5.3 AmbioPharm Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 AmbioPharm Peptide CDMO Product Portfolio
  30. 6.5.5 AmbioPharm Recent Developments
  31. 6.6 USV Peptides
  32. 6.6.1 USV Peptides Company Information
  33. 6.6.2 USV Peptides Business Overview
  34. 6.6.3 USV Peptides Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 USV Peptides Peptide CDMO Product Portfolio
  36. 6.6.5 USV Peptides Recent Developments
  37. 6.7 Thermofischer
  38. 6.7.1 Thermofischer Company Information
  39. 6.7.2 Thermofischer Business Overview
  40. 6.7.3 Thermofischer Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Thermofischer Peptide CDMO Product Portfolio
  42. 6.7.5 Thermofischer Recent Developments
  43. 6.8 PolyPeptide
  44. 6.8.1 PolyPeptide Company Information
  45. 6.8.2 PolyPeptide Business Overview
  46. 6.8.3 PolyPeptide Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 PolyPeptide Peptide CDMO Product Portfolio
  48. 6.8.5 PolyPeptide Recent Developments
  49. 6.9 Piramal Pharma
  50. 6.9.1 Piramal Pharma Company Information
  51. 6.9.2 Piramal Pharma Business Overview
  52. 6.9.3 Piramal Pharma Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Piramal Pharma Peptide CDMO Product Portfolio
  54. 6.9.5 Piramal Pharma Recent Developments
  55. 6.10 JPT
  56. 6.10.1 JPT Company Information
  57. 6.10.2 JPT Business Overview
  58. 6.10.3 JPT Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 JPT Peptide CDMO Product Portfolio
  60. 6.10.5 JPT Recent Developments
  61. 6.11 CPC Scientific
  62. 6.11.1 CPC Scientific Company Information
  63. 6.11.2 CPC Scientific Business Overview
  64. 6.11.3 CPC Scientific Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 CPC Scientific Peptide CDMO Product Portfolio
  66. 6.11.5 CPC Scientific Recent Developments
  67. 6.12 CordenPharma
  68. 6.12.1 CordenPharma Company Information
  69. 6.12.2 CordenPharma Business Overview
  70. 6.12.3 CordenPharma Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 CordenPharma Peptide CDMO Product Portfolio
  72. 6.12.5 CordenPharma Recent Developments
  73. 6.13 CBL
  74. 6.13.1 CBL Company Information
  75. 6.13.2 CBL Business Overview
  76. 6.13.3 CBL Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 CBL Peptide CDMO Product Portfolio
  78. 6.13.5 CBL Recent Developments
  79. 6.14 Bio Basic
  80. 6.14.1 Bio Basic Company Information
  81. 6.14.2 Bio Basic Business Overview
  82. 6.14.3 Bio Basic Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Bio Basic Peptide CDMO Product Portfolio
  84. 6.14.5 Bio Basic Recent Developments
  85. 6.15 Bachem
  86. 6.15.1 Bachem Company Information
  87. 6.15.2 Bachem Business Overview
  88. 6.15.3 Bachem Peptide CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Bachem Peptide CDMO Product Portfolio
  90. 6.15.5 Bachem Recent Developments
7 North America
  1. 7.1 North America Peptide CDMO Market Size (2021-2032)
  2. 7.2 North America Peptide CDMO Market Size by Type
  3. 7.2.1 North America Peptide CDMO Market Size by Type (2021-2026)
  4. 7.2.2 North America Peptide CDMO Market Size by Type (2027-2032)
  5. 7.2.3 North America Peptide CDMO Market Share by Type (2021-2032)
  6. 7.3 North America Peptide CDMO Market Size by Application
  7. 7.3.1 North America Peptide CDMO Market Size by Application (2021-2026)
  8. 7.3.2 North America Peptide CDMO Market Size by Application (2027-2032)
  9. 7.3.3 North America Peptide CDMO Market Share by Application (2021-2032)
  10. 7.4 North America Peptide CDMO Market Size by Country
  11. 7.4.1 North America Peptide CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Peptide CDMO Market Size by Country (2021-2026)
  13. 7.4.3 North America Peptide CDMO Market Size by Country (2027-2032)
  14. 7.4.4 North America Peptide CDMO Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Peptide CDMO Market Size (2021-2032)
  2. 8.2 Europe Peptide CDMO Market Size by Type
  3. 8.2.1 Europe Peptide CDMO Market Size by Type (2021-2026)
  4. 8.2.2 Europe Peptide CDMO Market Size by Type (2027-2032)
  5. 8.2.3 Europe Peptide CDMO Market Share by Type (2021-2032)
  6. 8.3 Europe Peptide CDMO Market Size by Application
  7. 8.3.1 Europe Peptide CDMO Market Size by Application (2021-2026)
  8. 8.3.2 Europe Peptide CDMO Market Size by Application (2027-2032)
  9. 8.3.3 Europe Peptide CDMO Market Share by Application (2021-2032)
  10. 8.4 Europe Peptide CDMO Market Size by Country
  11. 8.4.1 Europe Peptide CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Peptide CDMO Market Size by Country (2021-2026)
  13. 8.4.3 Europe Peptide CDMO Market Size by Country (2027-2032)
  14. 8.4.4 Europe Peptide CDMO Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Peptide CDMO Market Size (2021-2032)
  2. 9.2 China Peptide CDMO Market Size by Type
  3. 9.2.1 China Peptide CDMO Market Size by Type (2021-2026)
  4. 9.2.2 China Peptide CDMO Market Size by Type (2027-2032)
  5. 9.2.3 China Peptide CDMO Market Share by Type (2021-2032)
  6. 9.3 China Peptide CDMO Market Size by Application
  7. 9.3.1 China Peptide CDMO Market Size by Application (2021-2026)
  8. 9.3.2 China Peptide CDMO Market Size by Application (2027-2032)
  9. 9.3.3 China Peptide CDMO Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Peptide CDMO Market Size (2021-2032)
  2. 10.2 Asia Peptide CDMO Market Size by Type
  3. 10.2.1 Asia Peptide CDMO Market Size by Type (2021-2026)
  4. 10.2.2 Asia Peptide CDMO Market Size by Type (2027-2032)
  5. 10.2.3 Asia Peptide CDMO Market Share by Type (2021-2032)
  6. 10.3 Asia Peptide CDMO Market Size by Application
  7. 10.3.1 Asia Peptide CDMO Market Size by Application (2021-2026)
  8. 10.3.2 Asia Peptide CDMO Market Size by Application (2027-2032)
  9. 10.3.3 Asia Peptide CDMO Market Share by Application (2021-2032)
  10. 10.4 Asia Peptide CDMO Market Size by Country
  11. 10.4.1 Asia Peptide CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Peptide CDMO Market Size by Country (2021-2026)
  13. 10.4.3 Asia Peptide CDMO Market Size by Country (2027-2032)
  14. 10.4.4 Asia Peptide CDMO Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Peptide CDMO Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Peptide CDMO Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Peptide CDMO Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Peptide CDMO Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Peptide CDMO Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Peptide CDMO Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Peptide CDMO Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Peptide CDMO Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Peptide CDMO Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Peptide CDMO Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Peptide CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Peptide CDMO Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Peptide CDMO Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Peptide CDMO Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst